Recognised for Best Use of Thought Leadership with Boehringer Ingelheim, and for Strategy with NHS South West London Integrated Care Board
We are proud to announce that CF (Carnall Farrar) has won two categories at the Management Consultancies Association (MCA) Awards 2026: Best Use of Thought Leadership, for our work with Boehringer Ingelheim on chronic kidney disease, and Strategy, for our work with NHS South West London Integrated Care Board (ICB).
The awards, announced last night at London’s Grosvenor House, recognise excellence and innovation across the UK consulting sector. With these wins, our work has now been recognised at the MCA Awards, as a winner or highly commended, for nine consecutive years.
The winning work
Best Use of Thought Leadership, with Boehringer Ingelheim
In partnership with Boehringer Ingelheim, we produced a national case for change on chronic kidney disease (CKD) in England, a condition affecting more than seven million people. The analysis showed that CKD is linked to 11% of cardiovascular deaths and exposed stark, deprivation-driven inequalities in both diagnosis and treatment. Our modelling found that earlier identification and treatment at scale could save more than 6,000 lives a year. A Greater Manchester case study showed how the national evidence can translate into local commissioning decisions.
Read the full entry here.
Strategy, with NHS South West London ICB
NHS South West London ICB commissioned CF to develop a 10-year clinically-led strategic plan for its 1.9 million residents across six London Boroughs. Using our Health Strata population segmentation tool, we identified more than £1.2 billion in opportunities across commissioner and provider organisations. The plan is projected to prevent 28,000 people from developing a serious health condition, reduce the number of hospital beds needed by 17%, and move the system from significant deficit to surplus by 2035/36. All five acute Trusts in South West London have since adopted the forecasts as the basis for their own strategic planning.
Read the full entry here.
Hannah Farrar, CF Chief Executive Officer and Founder, said:
“We are delighted to win in both categories, and we share these awards with our clients. Our work with Boehringer Ingelheim brought the scale of chronic kidney disease, and the inequalities within it, into clear view. In South West London, the ICB and Trusts now have a shared plan for the next decade and the tools to keep it current. Both reflect what we care about most: evidence that leads to action and to better health for people. Thank you to our teams, our clients, the judges and the MCA.”
Ben Richardson, Managing Partner Life Sciences and Health Investing, said:
“We thank our clients for putting their confidence in us. These projects are cutting-edge approaches to the use of the world’s best longitudinal linked data sets. They’ve created new insights that health systems and life sciences companies can act on to achieve a triple win for patients, health systems and the companies partnering with them. The South West London work revealed the drivers of healthcare cost and offers a routemap for better outcomes for the money being spent. The Boehringer Ingelheim work shone a spotlight on stages 1 and 2 of chronic kidney disease as a missed opportunity to avoid progression to dialysis and transplants. In both cases they are examples of how clients are pursuing the need to test, diagnose and treat patients to target to improve population health.”
A year of growth
2026 has been a year of growth for CF. Following our full launch in Saudi Arabia in 2025, we are expanding into Ireland and exploring a new base in the north of England, bringing our team closer to the clients and communities we serve.
Our team is growing to match. We continue to hire across the business and are investing in new data platforms that strengthen our analytical capabilities. We support clients across the health sector with some of their most complex challenges: large-scale system transformation and finance and performance improvement for the NHS, growth for health investors, and faster uptake of innovation for life sciences companies.
Congratulations to all of this year’s finalists and winners. The full list of winners is available on the MCA website.
Pictured above: Hannah Farrar (CF), Dr Jo Andrews (CF), Ben Richardson (CF), Jack Rowlandson (CF), Maddie Housden (CF), Ivan Markov (CF), Arthur Chitnis (CF), Dr Ozlem Yildiz (CF), Ioannis Katsoulis (CF), Alisa Kamynina (CF), Gavin Dreyer (Barts NHS), Karen Fox (Boehringer Ingelheim), Naj Rotheram (Boehringer Ingelheim), James Bevan (Boehringer Ingelheim).
About CF
CF is a leading consultancy with a purpose to make an enduring impact on health and healthcare. We work with leaders and frontline teams to improve health, transform healthcare, drive adoption of innovation and create value through investment.
Our consultancy serves the entire healthcare sector, from payors and providers of care to life science companies, health tech and sector suppliers and health investors. We provide end-to-end services, from strategy through implementation, accelerated by data, digital and AI . We shape opinion through evidence-based thought leadership on key issues affecting health. With unmatched ability to access to health data, our consultants are a driving force for delivering positive and meaningful change.
CF headquarters are in London with Middle East headquarters in Riyadh, we serve clients in the UK and across Europe and the Middle East.
